Embryonic stem (ES) cells are a promising source of cardiomyocytes, but clinical application of ES cells has been hindered by the lack of reliable selective differentiation methods. Differentiation into any lineage is partly dependent on the regulatory mechanisms of normal early development. Although several signals, including bone morphogenetic protein (BMP) 1,2 , Wnt 3 and FGF 4 , are involved in heart development, scarce evidence is available about the exact signals that mediate cardiomyocyte differentiation. While investigating the involvement of BMP signaling in early heart formation in the mouse, we found that the BMP antagonist Noggin is transiently but strongly expressed in the heartforming region during gastrulation and acts at the level of induction of mesendoderm to establish conditions conducive to cardiogenesis. We applied this finding to develop an effective protocol for obtaining cardiomyocytes from mouse ES cells by inhibition of BMP signaling.
Embryonic stem (ES) cells are a promising source of cardiomyocytes, but clinical application of ES cells has been hindered by the lack of reliable selective differentiation methods. Differentiation into any lineage is partly dependent on the regulatory mechanisms of normal early development. Although several signals, including bone morphogenetic protein (BMP) 1,2 , Wnt 3 and FGF 4 , are involved in heart development, scarce evidence is available about the exact signals that mediate cardiomyocyte differentiation. While investigating the involvement of BMP signaling in early heart formation in the mouse, we found that the BMP antagonist Noggin is transiently but strongly expressed in the heartforming region during gastrulation and acts at the level of induction of mesendoderm to establish conditions conducive to cardiogenesis. We applied this finding to develop an effective protocol for obtaining cardiomyocytes from mouse ES cells by inhibition of BMP signaling.
BMP signaling is crucial in mesodermal induction and cardiac formation 1, 2 . However, simple stimulation with BMP2/BMP4 did not augment or suppress cardiomyocyte induction from ES cells (data not shown). In the vertebrate nervous system, Noggin and other BMP inhibitors (chordin and follistatin) are involved in neural differentiation in a context-dependent fashion 5, 6 . We hypothesized that BMP antagonists may also be involved in cardiomyocyte induction. Here, we performed whole-mount in situ hybridization for various BMP antagonists on mouse embryos at different gastrulation stages. The BMP antagonist Noggin was transiently but strongly expressed in the heart-forming area (Fig. 1a,b) . It was clearly expressed at the cardiac crescent at mouse embryo day E7.5 and the late crescent stage at E8.0, but was barely detectable in the linear heart tube after E8.5. In contrast, the expression of Noggin at the notochord continued after E8.5, as reported previously 7, 8 . Sectioning of wholemount samples from E7.5 and E8.0 showed expression of Noggin in both the endodermal and mesodermal layers and made clear that Noggin was derived from the primary heart field ( Fig. 1c,d ). This marked difference in the time course of Noggin expression between the heart-forming region and notochord suggested that transient expression of Noggin functions in cardiomyocyte differentiation.
We stimulated mouse ES cells in suspension cultures with Noggin in various ways (Fig. 2a,b) . We administered Noggin before or after embryoid body formation to mimic the transient and strong expression of Noggin at the early gastrulation stage. Discontinuation of leukemia inhibitory factor (LIF) and addition of Noggin before or after embryoid body formation did not increase the incidence of formation of spontaneously beating embryoid bodies (Fig. 2b, rows  2,3) . Interestingly, addition of Noggin on day 0 and discontinuation of LIF on day 3 slightly but substantially increased the beating embryoid body incidence (Fig. 2b, row 4) , suggesting that the optimal timing for Noggin might be both before and after embryoid body formation. Next, we added Noggin at either À3, 0, +1, +2 or +3 d (Fig. 2b , rows 5-9), and LIF before embryoid body formation. Although Noggin at day 0 (Fig. 2b, row 6 ) slightly increased the beating embryoid body incidence, this incidence gradually decreased at the later time points. Based on these results, we administered Noggin at day -3 and day 0 from embryoid body formation. This led to a marked increase in beating embryoid body incidence to 95.3% at 10 d (Fig. 2b , rows 10-16), and continued growth of embryoid bodies to day 14. These results suggest that the cardiomyocyte inductive activity of Noggin was restricted to the period from 3 d before one day after embryoid body formation and that the ES cells must initially be undifferentiated.
This protocol was effective in two independent ES cell lines, EB3 and R1, and the optimal concentration of Noggin was 150 ng/ml ( Fig. 2c and Supplementary Fig. 1 online). To demonstrate that this effect was specific to inhibition of the BMP pathway, we administered various concentrations of BMP2 at day 0 (Fig. 2d) . Even low doses of BMP2 strongly inhibited Noggin-dependent cardiomyocyte induction. To confirm that the inhibition of BMP signaling in the early phase of differentiation could accelerate cardiomyocyte induction, soluble BMP receptor-1A (BMPR-1A) or another BMP antagonist, chordin, was also administered, and cardiomyocyte induction was observed. Both interventions augmented the incidence of beating in individual embryoid bodies (Fig. 2e) . In contrast, administration of various growth factors, including insulin-like growth factor-1 (IGF-1), fibroblast growth factor (FGF2) and BMP2, using the same protocol did not boost cardiomyocyte induction (Fig. 2f) . These results suggest that inhibition of BMP signaling in the undifferentiated or immediate early phase of ES cell differentiation is crucial for cardiomyocyte differentiation.
Next, we examined which step of cardiomyocyte development Noggin acted upon. Noggin-treated ES cells expressed markedly higher levels of brachyury T than untreated cells, and then showed strong induction of cardiomyocyte marker gene expression (Nkx2.5 and Tbx5). Despite this increase in brachyury-T expression, the expression of other early mesodermal markers transiently increased but then subsequently decreased (Fig. 2g) . We also performed whole mount in situ hybridization of the embryoid bodies, and quantified these mesodermal marker-positive cells (Fig. 2h,i) . Taken together, these data suggest that Noggin acts principally between the undifferentiated and brachyury-T-positive states. Brachyury T is a marker of mesendodermal progenitors that can differentiate into mesoderm or endoderm depending on culture conditions 9 . In our experiments, Noggin increased both the proportion of the cells expressing brachyury T by 1.8-fold and the level of brachyury-T mRNA per cell by sixfold (Fig. 2j) . This suggests that an increase in mRNA per cell is essential for cardiomyocyte induction from undifferentiated ES cells, and that there may be subpopulations within the brachyury-T-positive cells that can be distinguished by their levels of expression. The increase in cells expressing high levels of brachyury T that formed mesendoderm resulted in the large increase in Nkx2.5-positive cells.
To quantify the incidence of cardiomyocyte induction with Noggin treatment, we immunostained for cardiac-specific proteins and observed the results by confocal laser microscopy. Most cells in the Noggin-treated embryoid bodies stained positive for myosin heavy chain (MHC), myosin light chain (MLC), atrial natriuretic peptide (ANP), cardiac troponin I and sarcomeric actinin ( Fig. 3a-c) . In contrast, the cardiomyocyte content was markedly lower in the control or in embryoid bodies treated with other Noggin protocols. The optimal Noggin protocol led to synchronous beating of the entire embryoid body (see Supplementary Video online). The isolated cells expressed many cardiac markers and had a typical cardiac myocyte morphology. At day 10, the embryoid bodies were attached to the gelatin-coated dishes and stained with anti-MHC antibodies. There was an B100-fold increase in the number of cardiomyocytes compared with control.
The Noggin protocol efficiently induced expression of cardiac transcription factors, including Nkx2.5, GATA4, TEF1, Tbx5 and MEF2C, whereas expression of the stem cell marker Oct3/4 rapidly decreased (Fig. 3d) . Cardiac-specific proteins were also strongly induced, including ANP, brain natriuretic peptide, MLC-2v, MLC2a, a-MHC, b-MHC and a-cardiac actin. Western blot analysis revealed that the Noggin-treated embryoid bodies expressed GATA4, troponin I, MLC and ANP at levels that were 10-to 450-fold higher than those seen with the other protocol (Fig. 3e,f) . To investigate whether this inductive phenomenon was cell autonomous or nonautonomous, we treated ES cells stably transfected with the gene encoding green fluorescent protein (GFP) with Noggin, and then combined them with untreated GFP -ES cells just before embryoid body formation. The majority of GFP + , Noggin-treated ES cells differentiated into cardiomyocytes in the embryoid bodies, whereas very few GFP -untreated ES cells became cardiomyocytes (Fig. 3g,h ). These findings suggest that Noggin-mediated induction of cardiomyocyte formation is a cell-autonomous phenomenon.
A number of growth factors and chemical compounds induce cardiomyocyte differentiation of mouse ES cells, including reactive oxygen species (2.7-fold increase in beating embryoid body incidence) 10 , TGFb plus BMP2 (threefold increase) 11 , targeting of RBP-Jk (downstream of notch signaling)-gene (20-fold increase) 12 , ascorbic acid (fivefold increase) 13 , as well as IGF-1, FGF, oxytocin, erythropoietin, retinoic acid and dimethyl sulfoxide [14] [15] [16] . To our knowledge, however, no previous protocol for increasing cardiomyocyte differentiation is as efficient as our present protocol (approximately 100-fold increase in the number of cardiomyocytes compared with control). The efficiency of our protocol may reflect the fact that it makes use of endogenous factors and is modeled on in vivo cardiomyoctye induction.
Accumulating evidence implicates BMP signaling as a potent heartinductive signal. Administration of BMP-2/BMP-4 to explant cultures from chicken embryo induces full cardiac differentiation in stages 5-7 anterior medial mesoderm, a tissue that is normally not cardiogenic 17, 18 . In contrast, before stage 3 or during early stages of gastrulation, both BMP2 and BMP4 inhibit cardiomyogenesis 19 . Although BMPs are expressed in lateral plate mesoderm including the anterior lateral plate 20 , stimulation of ES cells by BMP2 or BMP4 does not augment cardiomyocyte differentiation. Together, these findings suggest that BMPs play multiple roles in mesodermal induction and specific organ differentiation and that their temporal and spatial expression is critical in cardiomyocyte induction 19 .
In the vertebrate nervous system, the local action of Noggin and other BMP inhibitors on BMP signaling is very important in neural induction, in patterning during embryonic development and in adult neurogenesis 21 . In Xenopus laevis gastrula-stage embryos, Noggin and other BMP inhibitors are secreted by the Spemann organizer and induce neural tissue from dorsal ectoderm 7, 22, 23 by inhibiting ectodermal BMPs 24 . In the developing neural tubes, BMP has been shown to specify the dorsal fates of neural progenitor cells 25 . BMP inhibitors are also expressed in ventral somites or in the notochord, suggesting that some are involved in a counter gradient of BMP activity along the dorso-ventral axis.
Based on the analogy to the central nervous system, we suspected that the context-dependent differential action of BMPs in cardiomyocyte induction might be explained by local action of Noggin and other BMP inhibitors. We found that Noggin is transiently but strongly expressed at the anterolateral plate in mouse embryos at E7.0-E8.0 and is critical in cardiomyocyte induction. The restricted and highly effective window of Noggin's inductive action for cardiomyocyte differentiation from ES cells exactly matched the normal developmental conditions in the heart-forming area in E7.0-E8.0 embryos. From the present results, we propose that BMP signaling is essential for at least two steps in the cardiomyocyte induction process: mesodermal induction 26 and cardiomyocyte differentiation 1, 2 . However, between these steps, a transient block of intrinsic BMP signaling may be the most important step for determining cardiomyogenic differentiation.
METHODS
Whole-mount in situ hybridization. Pregnant ICR wild-type mice were purchased from Japan CLEA. All experiments were approved by the Keio University Ethics Committee for Animal Experiments. Mice from embryonic day (E) 7.5, 8.0, 8.25, 8.5 and 9.0 were removed, and whole-mount in situ hybridization was performed using digoxigenin-labeled RNA probes as described 27 . The full-length cDNAs for mouse Noggin and nkx2.5 (accession number NM_008711 and NM_008700, respectively) were obtained by RT-PCR and subcloned into pBluescript plasmid. The cDNAs for mouse Tbx5 and brachyury T were kindly provided by H. Yamagishi and H. Bernhard, respectively. The probes were transcribed with T3 or T7 RNA polymerase.
Cell culture. Mouse embryonic fibroblast-free ES cells were used. Undifferentiated ES cells (EB3 28 , R1 29 ) were maintained on gelatin-coated dishes in GMEM supplemented with 10% FBS (Equitechbio), 2 mM L-glutamine, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 0.1 mM 2-mercaptoethanol and 2,000 U/ml murine LIF (Chemicon International).
EB3 cells (a kind gift from H. Niwa, Riken, Japan), which carry the blasticidin S-resistant selection marker gene driven by the Oct3/4 promoter (active in the undifferentiated status) were maintained in medium containing 20 mg/ml blasticidin S to eliminate differentiated cells. EB3 is a subline derived from E14tg2a ES cells 30 , and was generated by targeted integration of the Oct3/4-IRES-BSD-pA vector 28 into the Oct3/4 allele.
Differentiation of ES cells. ES cells were cultured on gelatin-coated dishes in
a-MEM supplemented with 10% FBS (Equitechbio), 2 mM L-glutamine, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 0.1 mM 2-mercaptoethanol, 2,000 U/ml LIF and 0.15 mg/ml Noggin (Noggin-Fc, R&D) for 3 d. Then, the cells were trypsinized, and cultured to form spheroids (embryoid bodies) from a single cell using a three-dimensional culture system in the same medium as described above minus the LIF on uncoated Petri dishes to induce embryoid bodies. FGF2, IGF-1, BMP2, chordin and BMP receptor-1A/Fc (BMPR-1A) were purchased from R&D.
Histological and immunohistochemical analysis. Embryoid bodies (12-14 d) were fixed in 4% paraformaldehyde for 45 min and embedded using Tissue-Tek OCT (Sakura Finetek). In some experiments, the isolated cells were plated on gelatin-coated glass coverslips at low density and fixed in 4% paraformaldehyde for 5 min. The samples were exposed to primary antibodies including anti-MHC (MF20), anti-troponin I (C-19, Santa Cruz Biotechnology; 1:500), anti-actinin (EA-53, Sigma; 1:800), anti-ANP (CHEMICON; 1:100), and anti-MLC (P-18, Santa Cruz; 1:500). Bound antibodies were visualized using a secondary antibody conjugated with Alexa488. Nuclei were stained with 4¢,6-diamidine-2-phenylidole dihydrochloride (DAPI; Sigma Aldrich) or propidium iodide (PI, Sigma), TOTO3 (Molecular Probes). The percentage of MHC-expressing cells was quantified using the day-12 embryoid bodies.
RT-PCR and real-time quantitative PCR. Total RNA was extracted using Trizol reagent (GIBCO) and RT-PCR was performed as described previously 28 . At least five replicates were done for each time point. The PCR primers are listed in the Supplementary Table 1 online. Before quantitative analysis, the linear range of the PCR cycles was measured for each gene, and the appropriate number of PCR cycles was determined. GAPDH was used as an internal control. For quantitative analysis of brachyury T, Nkx2.5, Tbx5, Flk1 and GATA1 expression, cDNA was used as template in a TaqMan real-time PCR assay using the ABI Prism 7700 sequence detection system (Applied Biosystems) according to the manufacturer's instructions. All samples were run in triplicate. Data were normalized to GAPDH. The primers and TaqMan probe for brachyury T, Nkx2.5, Tbx5, Flk1 and GATA1 were Mm00436877_m1, Mm00657783_m1, Mm00803521_m1, Mm00440099_m1, and Mm00484678_m1 (Applied Biosystems), respectively.
Western blotting. Embryoid bodies were lysed in a buffer containing 20 mmol/l Tris-HCl (pH 7.4), 100 mmol/l NaCl, 5 mmol/l EDTA, 1.0% Triton X-100, 10% glycerol, 0.1% SDS, 1.0% deoxycholic acid, 50 mmol/l NaF, 10 mmol/l Na 3 P 2 O 7 , 1 mmol/l Na 3 VO 4 , 1 mmol/l phenylmethylsulfonyl fluoride, 10 mg/ ml aprotinin, and 10 mg/ml leupeptin. Proteins were separated on 5% to 10% SDS-PAGE. Western blot analysis was performed as described previously 29 . Rabbit polyclonal antibodies against GATA4 (Santa Cruz Biotechnology), troponin I, MLC and ANP were used as primary antibodies, and peroxidaseconjugated goat anti-rabbit IgG was used as a secondary antibody. Signals were visualized with an ECL kit (Amersham).
Statistical analysis. The data were processed using StatView J-4.5 software. Values are reported as means 7 s.d. Comparisons among values for all groups were performed by one-way ANOVA. The Scheffe's F test was used to determine the level of significance. The probability level accepted for significance was P o 0.05.
Note: Supplementary information is available on the Nature Biotechnology website.
